The blood-brain barrier, a specialized physiological shield, prevents most conventional chemotherapeutics from adequately reaching brain tumors, creating a significant pharmacological obstacle. Concurrently, the central nervous system exhibits an inherently “cold” immune microenvironment — a state characterized by limited immune activity — which further complicates efforts to mount an effective immune response against residual glioblastoma cells that infiltrate healthy brain tissue and evade surgical excision. Traditional post-surgical wafers releasing radiation or chemotherapeutic agents suffer from a lack of specificity and limited clinical efficacy, underscoring the urgent need for innovative, targeted therapies.

Jonathan Forbes, MD, principal investigator and neurosurgery expert at UC, emphasizes the unprecedented opportunity surgery offers. The resection cavity, a surgically accessible void left behind after tumor removal, is microscopically burdened with infiltrative cancer cells challenging to eradicate. By deploying an immunotherapeutic device directly within this microsite, the strategy aims to manipulate the local immune environment precisely where residual malignant cells persist, potentially transforming the brain from an immunologically inert zone into a robust battleground against cancer.

Selecting the optimal immunostimulatory molecule was paramount. The investigation converged on Interleukin-15 (IL-15), a cytokine known for its potent activation of immune effector cells integral to cancer cell recognition and destruction. IL-15 not only promotes the survival and proliferation of natural killer cells and cytotoxic T lymphocytes but also enhances their cytolytic capacity, hallmark features essential for orchestrating a coordinated immune assault on glioblastoma, which notoriously resists many conventional immunotherapies.

The Ride Cincinnati grant of $40,000 is integral to advancing validation experiments utilizing a revolutionary glioblastoma-on-a-chip platform, developed collaboratively with biomedical engineer Ricardo Barrile, PhD. This technology transcends the limitations of traditional cell culture and animal models by fabricating a three-dimensional, human-relevant microphysiological system. The chip mimics the native brain tumor microenvironment, integrating human brain cells alongside glioblastoma cells with precision-engineered vascular and immune system analogs, enabling detailed interrogation of drug effects in a controlled and clinically pertinent context.

Barrile’s engineering feat leverages advanced 3D bioprinting and microfluidic systems to recreate crucial biological interfaces. The chip incorporates a bioprinted blood vessel channel simulating drug transport dynamics from the bloodstream into brain tissue, and an immune cell compartment allowing real-time observation of immune-tumor interactions. This innovative mimicry recapitulates the tumor’s complex ecosystem — essential for predicting therapeutic outcomes more accurately than conventional models, where immune components are often absent or diminished.

The significance of incorporating immune system elements cannot be overstated. Glioblastoma tumors in patients contain up to 30% immune cells, which play nuanced roles in tumor progression and resistance. Typical in vitro assays fail to preserve this heterogeneity, limiting their translational relevance. The glioblastoma-on-a-chip model’s inclusion of various immune cell populations offers a transformative tool for dissecting immune modulation by novel therapeutics such as the IL-15 wafer, enabling mechanistic insights into immune activation, suppression, and cytotoxicity within a human brain tumor milieu.

Looking toward personalized medicine, the platform holds promise for individualized therapeutic screening. By utilizing patient-derived cells on the chip, the researchers aim to simulate a patient’s unique tumor-immune landscape, providing a predictive assay to tailor immunotherapy regimens before clinical deployment. This approach could revolutionize glioblastoma management by moving away from generic treatment protocols toward bespoke strategies that maximize efficacy and minimize adverse effects.

In parallel, the UC Brain Tumor Center is pioneering methods to circumvent the blood-brain barrier’s impermeability using navigated focused ultrasound, a technique capable of transiently opening the barrier to facilitate drug delivery. When integrated with immunomodulatory wafers and physiologically accurate in vitro models, these multifaceted strategies represent a comprehensive assault on glioblastoma’s biological defenses, bringing new hope to an area where therapeutic advances have been stubbornly elusive for decades.

The interdisciplinary nature of this research, merging molecular immunology, biomedical engineering, and neurosurgical clinical practice, exemplifies modern biomedical innovation. Medical student Beatrice Zucca’s involvement highlights the project’s educational impact, fostering a new generation of researchers equipped to tackle complex challenges through cross-disciplinary collaboration. The work not only advances scientific knowledge but also carries profound personal significance for those engaged in the quest to develop curative therapies for one of the deadliest cancers known.

Continued support and expansion of such initiatives are vital to unravel glioblastoma’s layered pathology and to harness the full potential of the immune system in combating this devastating disease. By capitalizing on technological innovations like glioblastoma-on-a-chip and immunostimulatory therapeutic wafers, the University of Cincinnati team is charting a path toward more effective, patient-specific treatment paradigms that could markedly improve prognosis and quality of life for patients worldwide.

Subject of Research: Glioblastoma treatment and immunotherapy
Article Title: University of Cincinnati Pioneers Glioblastoma-on-a-Chip for Targeted Immunotherapy
News Publication Date: 2024
Web References: https://www.uc.edu/news/articles/2024/09/new-biotech-targets-brain-tumor-treatments.html
Image Credits: Photo/Andrew Higley/UC Marketing + Brand
Keywords: Glioblastomas, Brain cancer, Immunotherapy, Glioblastoma-on-a-chip, Interleukin-15, Biomedical engineering, 3D bioprinting, Microfluidics, Personalized medicine, Blood-brain barrier

This innovative system is poised to become a game-changer by addressing the critical limitation of current CAR-T therapies—their inability to effectively penetrate and operate within solid malignancies. Using human tumor explants derived from lung adenocarcinoma patients, the researchers created a vascularized, perfusable microenvironment on a chip that faithfully mimics the spatial and biochemical landscape of real tumors. The platform not only simulates the architecture of tumor vasculature but also enables controlled introduction and dynamic observation of CAR-T cells as they navigate and engage cancer cells in real time.

At its core, the tumor-on-a-chip leverages microengineering techniques to cultivate human tumors with a functional microvascular network, painstakingly recreating the nutrient flow and immune cell trafficking found in human physiology. This vascularization is critical; it supplies oxygen, nutrients, and signaling molecules, while facilitating immune cell infiltration—factors often absent in conventional culture models. The system’s capability to deliver immune cells via perfusion channels mimics natural trafficking through blood vessels, offering a true-to-life context for studying immune interactions rarely achievable in static, two-dimensional assays.

In experiments with lung adenocarcinoma tumor explants, the researchers visualized CAR-T cells navigating through the vascularized tumor landscape, tracking their movement, activation, and cytotoxic activity with high spatiotemporal resolution. This allowed the team to dissect how CAR-T cells overcome physical and immunosuppressive barriers characteristic of solid tumors. The study’s findings highlighted both the potential efficacy and the current limitations of CAR-T cells, revealing nuanced cell behaviors linked to tumor matrix composition, immune checkpoint expression, and metabolic constraints.

Building upon their success modeling lung adenocarcinoma, the team applied their platform to malignant pleural mesothelioma, another aggressive solid cancer notorious for its resistance to immunotherapy. Here, they tested a novel chemokine-directed CAR-T cell engineering strategy designed to enhance immune cell homing to tumor sites. By modifying CAR-T cells to express specific chemokine receptors, the researchers observed improved infiltration and tumor targeting on the chip, outcomes further validated in a complementary in vivo mouse model. This seamless integration of in vitro and in vivo validation emphasizes the platform’s utility for preclinical testing and personalized therapy optimization.

One of the most compelling aspects of this technology lies in its ability to reveal actionable therapeutic insights. Through global metabolomics analysis conducted on lung adenocarcinoma tumor explants cultured on the chip, the researchers identified distinct metabolic signatures that correlate with CAR-T cell efficacy. These findings uncovered potential metabolic checkpoints that could be pharmacologically targeted to augment CAR-T cell function. The identification of such metabolic vulnerabilities opens new avenues for combination therapies that could surmount tumor immunosuppression and resistance mechanisms.

Beyond immunotherapy, the tumor-on-a-chip represents a versatile tool for studying tumor biology under physiologically relevant conditions. It provides researchers a window into the dynamic interplay between cancer cells, stromal cells, immune populations, and the vascular niche within a controlled environment. This precision modeling can dramatically accelerate drug discovery, biomarker identification, and mechanistic studies, minimizing dependency on animal models and potentially revolutionizing personalized medicine approaches for solid tumors.

This work exemplifies the power of bioengineering to transcend conventional biological modeling, merging microfluidics, tissue engineering, and immunology into a unified platform. The tumor-on-a-chip system addresses longstanding hurdles in cancer research by bridging in vitro studies with clinical realities, thereby enabling a deeper understanding of immune resistance and therapeutic response patterns. Such sophisticated tools are indispensable as science moves toward the goal of engineering next-generation cell therapies tailored to the unique architecture and biology of individual tumors.

Additionally, the real-time visualization capabilities afforded by the platform elucidate critical stages of CAR-T cell function, from extravasation, migration, and tumor recognition to killing and exhaustion dynamics. Observing these processes in uninterrupted detail permits fine-tuning of CAR design, dosing strategies, and combination regimens much earlier in the development pipeline. This has profound implications, reducing costly late-stage failures in clinical trials and improving patient stratification strategies.

The platform also holds promise for expanding research into tumor heterogeneity—a significant factor in treatment resistance. By maintaining patient-derived tumor tissues with their intrinsic cellular diversity and microenvironmental features intact, the tumor-on-a-chip can capture how different cancer subpopulations respond variably to immunotherapy. This capability could guide the development of multi-pronged therapeutic strategies, integrating CAR-T cells with small molecules or biologics that target tumor complexity from multiple angles.

Furthermore, the innovation supports exploration of immune-suppressive elements such as regulatory T cells, myeloid-derived suppressor cells, and inhibitory checkpoint molecules within intact tumor ecosystems. Dissecting how these components interact with CAR-T cells in a native-like environment can reveal novel checkpoints for intervention. The ability to pharmacologically modulate these pathways and monitor CAR-T cell response offers a powerful feedback loop for optimizing treatment regimens.

Importantly, the study demonstrates that this microphysiological system is scalable, reproducible, and compatible with high-resolution imaging and omics analyses, positioning it as a robust platform for both academic and industrial research. Its adaptability allows incorporation of different tumor types, CAR constructs, and immune cell populations, making it a broadly applicable technology in the fight against cancer and other immunological diseases.

As the field advances, integration of this tumor-on-a-chip technology with artificial intelligence and machine learning could further enhance predictive modeling of CAR-T cell behavior, providing clinicians with sophisticated tools to customize therapy on a patient-by-patient basis. The convergence of engineering, immunology, and computational analytics heralds a new era in precision immunotherapy, where treatments are dynamically optimized based on real-time feedback from patient-derived tissue models.

In summary, this pioneering tumor-on-a-chip system marks a monumental step forward in overcoming the formidable biological barriers that have long stymied CAR-T cell efficacy in solid tumors. By faithfully replicating the tumor microenvironment and enabling detailed interrogation of immune cell function, it offers a transformative platform to accelerate research, improve therapeutic strategies, and ultimately bring the promise of CAR-T and other adoptive cell therapies to a broader range of patients suffering from solid cancers.

Subject of Research: Development of a microengineered tumor-on-a-chip platform to model and study CAR-T cell immunotherapy efficacy in human solid tumors.

Article Title: A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors.

Article References:
Liu, H., Noguera-Ortega, E., Dong, X. et al. A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02845-z

Image Credits: AI Generated

Liver cancer remains a formidable global health challenge, with hepatocellular carcinoma (HCC) constituting the majority of cases. Traditional treatment modalities, including transarterial embolization—a technique that introduces occluding agents to artificially starve tumors—depend heavily on animal models for preclinical evaluation. However, interspecies differences in vascular structure, immune response, and cellular microenvironments often obfuscate translational relevance. The newly developed vascularized liver tumor-on-a-chip circumvents these limitations by incorporating a perfusable microvasculature within a three-dimensional tumor spheroid matrix, closely recapitulating the biophysical and biochemical conditions found in human liver tumors.

This microfluidic organ-on-a-chip device integrates tumor spheroids surrounded by engineered, capillary-like vessels capable of sustaining continuous perfusion and oxygen exchange. By simulating the hepatic artery’s physiological flow, the platform allows precise delivery and controlled occlusion of embolic agents directly within the vascular network. This feature replicates clinical embolization procedures with remarkable fidelity, enabling real-time observation of vascular remodeling, tumor cell viability, and angiogenic signaling pathways following treatment.

One of the core technical achievements of this model lies in its ability to quantitatively assess embolic agent efficacy through sophisticated readouts. These include high-resolution imaging of vascular regression, multiplexed cytokine profiling to understand inflammatory and immune dynamics, and surface marker expression analyses that elucidate cellular stress responses. Such multidimensional data acquisition surpasses traditional in vitro cell culture and in vivo animal studies, offering a dynamic, human-relevant window into the molecular cascades triggered by embolization therapies.

By advancing an ethically favorable alternative to animal testing, this platform aligns with the National Institutes of Health’s mission to promote the development and adoption of non-animal methodologies in biomedical research. The liver cancer-on-a-chip embodies this vision by enabling mechanistic studies in a controlled environment that faithfully mirrors human tumor microenvironments, thereby improving the predictive value of preclinical trials and accelerating the pipeline for novel therapeutic agents.

The implications for drug development extend beyond embolization therapies alone. This vascularized model acts as a versatile testbed for exploring synergistic treatment regimens, including chemoembolization and radioembolization, where therapeutic agents or radioactive beads are co-delivered with embolic materials. Understanding the nuanced interplay between these modalities and tumor vasculature at a cellular level promises to refine precision oncology approaches, tailoring interventions based on patient-specific vascular and tumor characteristics.

Beyond therapeutic evaluation, the liver tumor-on-a-chip offers profound insights into tumor biology, especially concerning hypoxia-induced signaling, immune cell infiltration, and angiogenesis – processes that are notoriously difficult to study in vivo due to their complexity and spatial heterogeneity. This model enables researchers to meticulously dissect these phenomena, increasing comprehension of tumor progression and resistance mechanisms, ultimately guiding the design of interventions that can disrupt the tumor microenvironment more effectively.

The technical sophistication of the microengineered vessels supports variable flow patterns and mechanical forces, facets critical to liver tumor vascular biology. This ability to simulate physiological shear stress and perfusion pressure fosters a microenvironment that sustains endothelial cell function and vessel integrity, elements essential for accurate modeling of drug delivery and embolization dynamics. Additionally, the platform’s modular design facilitates scalability and adaptability for high-throughput screening, offering substantial promise for industrial and academic research applications alike.

Dr. Huu Tuan Nguyen, first author of the seminal publication describing this platform, emphasizes the system’s transformative potential: by capturing the unique vascular dynamics responsible for hepatocellular carcinoma growth and therapeutic response, the on-chip model challenges the existing paradigm reliant on simplifications and cross-species extrapolations. This advancement enables researchers to probe cellular-level interactions under clinically relevant conditions, translating complex vascular reperfusion and occlusion phenomena into quantifiable outcomes.

Furthermore, the platform promotes a deeper understanding of embolization-induced alterations in tumor immune landscapes. Given that immune cell populations and cytokine networks significantly influence therapeutic efficacy and tumor recurrence, the ability to monitor these parameters longitudinally in a human-relevant model provides invaluable data that may inform future immunotherapies in conjunction with embolic treatments.

Notably, the Terasaki Institute’s liver tumor-on-a-chip spearheads an integrative approach that merges bioengineering, oncology, and immunology, reflecting the institute’s commitment to translating fundamental research into practical, impactful biomedical innovations. The development of such organotypic microfluidic systems epitomizes the future of personalized medicine by enabling the testing of patient-derived tumor samples under conditions that closely mirror in vivo physiology without the ethical and biological constraints inherent in animal models.

As the global scientific community continues to grapple with the limitations of traditional cancer models, the vascularized embolization-on-a-chip represents a landmark achievement, setting a new standard for preclinical evaluation and offering hope for faster, safer translation of experimental therapies into the clinic. This advancement may profoundly influence not only liver cancer treatment paradigms but also broader applications across vascularized tumor types.

With publication in the journal Biofabrication in August 2025, this research lays a foundational platform that invites further exploration and collaborative innovation. The Terasaki Institute’s multifaceted approach to microfluidic system design, coupled with precise biological validation, signals a transformative shift in how researchers can emulate human disease conditions, study complex pathophysiology, and develop next-generation therapeutics with improved clinical relevance.

Contact with the principal investigator, Dr. Vadim Jucaud, is encouraged for those seeking to collaborate or learn more about this cutting-edge technology. As biomedical innovation continues to accelerate, models such as this will be indispensable tools in the pursuit of effective, patient-tailored cancer therapies that harmonize scientific rigor with ethical responsibility.

Subject of Research: Cells

Article Title: Embolization-on-a-chip: Novel Vascularized Liver Tumor Model for Evaluation of Cellular and Cytokine Response to Embolic Agents

News Publication Date: 3 September 2025

Web References: http://dx.doi.org/10.1088/1758-5090/adfbc3

References:
Jucaud, V., Nguyen, H. T., Peirsman, A., Khorsandi, D., Dokmeci, M. R. (2025). Embolization-on-a-chip: Novel Vascularized Liver Tumor Model for Evaluation of Cellular and Cytokine Response to Embolic Agents. Biofabrication. DOI: 10.1088/1758-5090/adfbc3

Image Credits: Terasaki Institute

Keywords: Cancer, Liver cancer, Biomedical engineering, Tissue engineering, Drug delivery